KemPharm, Inc. , a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced the addition of a new product candidate, KP879, which the company plans to develop as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD).

Medigene AG announced that it has entered into an exclusive license agreement with Leiden University Medical Center, the Netherlands, for worldwide rights to develop, manufacture, and commercialize an HA-1-specific T cell receptor (TCR) as a targeted immunotherapy for cancer.

Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, has announced a multi-target, integrated drug discovery collaboration with Sitryx Therapeutics, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.

PANTHERx® Specialty Pharmacy, The Rare Disease Specialty Pharmacy , and RxCrossroads  by McKesson, the leading commercial solutions partner for life sciences companies, announced their collaborative program to simplify the channel for precision medicine therapies.

RetiPharma, focusing on the development of products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to humans, is pleased to announce that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII).

Proprietary nasal delivery formulation of diazepam for the treatment of epilepsy developed by CDMO, Particle Sciences, a Lubrizol LifeSciences company, has been submitted as a New Drug Application (NDA) to the U.S. FDA by San-Diego-based Neurelis Inc.